Survival and late effects in children with stage 4 neuroblastoma

Pediatric Blood and Cancer

Volumn 57, Issue 4, 2011, Pages 629-635

  Perwein, Thomas ^a   Lackner, Herwig ^a   Sovinz, Petra ^a   Benesch, Martin ^a   Schmidt, Sandrin ^a   Schwinger, Wolfgang ^a   Urban, Christian ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Children; Late effects; Neuroblastoma; Survival

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; ISOTRETINOIN; MELPHALAN; TENIPOSIDE; THIOTEPA; TOPOTECAN; VINCRISTINE;

ARTICLE; BLINDNESS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DISEASE SEVERITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HEPATITIS B; HEPATOBILIARY DISEASE; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INCIDENCE; LIVER CELL CARCINOMA; LUNG DISEASE; MALE; MUSCULOSKELETAL DISEASE; NEUROBLASTOMA; OVERALL SURVIVAL; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND CANCER; SURVIVAL RATE; TOOTH DISEASE;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; INFANT; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; NEUROBLASTOMA; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVORS;

EID: 79961192900     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23036     Document Type: Article

References (32)

1. Deutsches Kinderkrebsregister. Jahresbericht. 2008. Available at: (accessed October 20, 2009).
2. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
3. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007; 369: 2106-2120.
4. Graf N. Neuroblastoma. In: Sitzmann FC, editor. Pädiatrie, 3rd edition. Stuttgart: Thieme; 2007. pp. 504-507.
5. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999; 341: 1165-1173.
6. Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: An INRG task force report. J Clin Oncol 2009; 27: 289-297.
7. Escobar MA, Grosfeld JL, Powell RL, et al. Long-term outcomes in patients with stage IV neuroblastoma. J Pediatr Surg 2006; 41: 377-381.
8. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 2003; 21: 1592-1601.
9. Kerbl R, Urban CE, Ambros IM, et al. Neuroblastoma mass screening in infancy: Insights into the biology of neuroblastic tumors. J Clin Oncol 2003; 21: 4228-4234.
10. Woods WG, Gao R-N, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med 2002; 346: 1041-1046.
11. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with autologous peripheral-blood stem cell-supported transplantation: Long-term survival update. J Clin Oncol 2006; 24: 2891-2896.
12. Trahair TN, Vowels MR, Johnston K, et al. Long-term outcomes in children with high-risk neuroblastoma treated with autologous stem cell transplantation. Bone Marrow Transplant 2007; 40: 741-746.
13. Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer 2008; 51: 679-683.
14. Laverdière C, Cheung N-KV, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005; 45: 324-332.
15. Laverdière C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101: 1131-1140.
16. 131I-metaiodobenzylguanidine. Cancer 2003; 97: 1332-1338.
17. Paulino AC, Mayr NA, Simon JH, et al. Locoregional control in infants with neuroblastoma: Role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys 2002; 52: 1025-1031.
18. van Santen HM, de Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005; 41: 1767-1774.
19. Flandin I, Hartmann O, Michon J, et al. Impact of TBI on late effects in children treated by megatherapy for stage IV neuroblastoma. A study of the French Society of Pediatric Oncology. Int J Radiat Oncol Biol Phys 2006; 64: 1424-1431.
20. Lackner H, Benesch M, Schagerl S, et al. Prospective evaluation of late effects after childhood cancer therapy with a follow-up over 9 years. Eur J Pediatr 2000; 159: 750-758.
21. Kushner BH, Budnick A, Kramer K, et al. Ototoxicity from high dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107: 417-422.
22. Parsons SK, Neault MW, Lehmann LE, et al. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant 1998; 22: 669-674.
23. Simon T, Hero B, Dupuis W, et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Pädiatr 2002; 214: 149-152.
24. Gurney JG, Tersak JM, Ness KK, et al. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics 2007; 120: 1229-1236.
25. Nève V, Foot ABM, Michon J, et al. Longitudinal clinical and functional pulmonary follow-up after megatherapy, fractionated total body irradiation, and autologous bone marrow transplantation for metastatic neuroblastoma. Med Pediatr Oncol 1999; 32: 170-176.
26. Lackner H, Moser A, Sovinz P, et al. Langzeitbetreuung junger Erwachsener nach Krebserkrankung im Kindesalter-Wohin führt der Weg? Wien Klin Wochenschr 2007; 119: 361-364.
27. National Cancer Institute. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: (accessed October 14, 2009).
28. Dickerman JD. The late effects of childhood cancer therapy. Pediatrics 2007; 119: 554-568.
29. 131I-metaiodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002; 94: 2081-2089.
30. Lackner H, Urban C, Sovinz P, et al. Hypothyroidism after treatment of metastatic neuroblastoma. Pediatr Blood Cancer 2010; 55: 768. published online in Wiley InterScience: DOI: 10.1002/pbc.22593.
31. Giorgiani G, Bozzola M, Locatelli F, et al. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. Blood 1995; 86: 825-831.
32. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 2001; 19: 2821-2828.